NeuroBo rises on positive pre-clinical data for liver treatment

MetaVia

22/05/2024 13:40

** Shares of NeuroBo Pharmaceuticals  NRBO.O  rise ~3% to
$4.72 premarket
    ** Co says pre-clinical data suggests that its drug DA-1241,
in combination with Novo Nordisk's  NOVOb.CO  weight-loss drug
Wegovy, helps in mitigating liver damage compared to either
treatment alone
    ** The combination therapy was tested in mice for the
treatment of liver tissue scarring in patients with metabolic
function-associated steatohepatitis (MASH)
    ** MASH, previously known as non-alcoholic steatohepatitis,
affects around 5% of the U.S. population
    ** Up to last close, stock up 23.9% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))